Back to search results

Video-Guided Acupuncture Imagery Treatment for Chemotherapy-induced Peripheral Neuropathy

This study is testing a new approach called Video-Guided Acupuncture Imagery Treatment (VGAIT) for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is nerve damage that can cause pain, tingling, or numbness after chemotherapy. VGAIT involves watching a video of acupuncture and imagining it's being done to you. This study is for women aged 18 to 80 who have had stage I-III breast cancer and still have CIPN symptoms after taxane-based chemotherapy. The main goal is to see if VGAIT is practical and if people like it and complete the study tasks. The study plans to enroll 20 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It is a pilot study to assess feasibility, with 20 planned participants.
What's involved
Participants will receive 16 sessions of VGAIT over 8 weeks remotely through Zoom. Study measures will be collected at enrollment, week 4, and week 8.
Compensation
Not stated in the trial record.
Follow-up
Feasibility outcomes are measured at 8 weeks, which is the duration of the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07177820

VGAIT for Chemotherapy-induced Peripheral Neuropathy

Recruiting
NAAges 18–80InterventionalSupportive care
Massachusetts General Hospital
~20 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:Video-Guided Acupuncture Imagery Treatment (VGAIT)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility related outcomes
Measured over 8 week

Conditions

Chemotherapy-induced Peripheral Neuropathy

Explore related trials

Breast CarcinomaChemotherapy-Induced Peripheral Neuropathy

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

Sierra Hodges
[email protected]
6177265004
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

at least 18 years of age
have histologically confirmed stage I-III breast cancer,
have completed adjuvant taxane-based chemotherapy (alone or in combination), ,
have an Eastern Cooperative Oncology Group performance status of 0 or 1, and reported grade 1 or greater CIPN symptoms for more than 2 weeks as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.

Exclusion

concurrent chemotherapy (there were no limitations on time from the last paclitaxel administration),
having metastatic or recurrent disease,
history of preexisting peripheral neuropathy prior to chemotherapy,
uncontrolled seizure disorder,
unstable cardiac disease or myocardial infarction within 6 months prior to study entry, being pregnant or nursing, or having used acupuncture for CIPN within 6 months prior to study entry.

What this trial measures

  • Feasibility related outcomes8 week

    Completion, satisfaction